WINTON GROUP Ltd Purchases New Shares in Integra LifeSciences Holdings Corporation $IART

WINTON GROUP Ltd purchased a new position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 102,632 shares of the life sciences company’s stock, valued at approximately $1,843,000.

A number of other institutional investors have also added to or reduced their stakes in IART. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after buying an additional 1,975 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Integra LifeSciences in the first quarter valued at approximately $277,000. Goldman Sachs Group Inc. increased its position in shares of Integra LifeSciences by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock valued at $36,515,000 after acquiring an additional 35,790 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Integra LifeSciences by 23.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock valued at $5,373,000 after acquiring an additional 45,693 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in Integra LifeSciences during the second quarter worth $491,000. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $15.50 on Friday. The firm’s 50 day moving average is $17.59 and its 200 day moving average is $14.60. The stock has a market capitalization of $1.21 billion, a P/E ratio of -172.20, a PEG ratio of 0.80 and a beta of 1.21. Integra LifeSciences Holdings Corporation has a 12 month low of $8.70 and a 12 month high of $20.49. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The business had revenue of $418.76 million during the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.46 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. Wall Street Zen cut Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Wells Fargo & Company boosted their price target on shares of Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. Citigroup restated a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Finally, BMO Capital Markets assumed coverage on shares of Integra LifeSciences in a report on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price objective for the company. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $18.86.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.